Medicinova | 10-Q: FY2025 Q3 Revenue: USD 123.32 K

Revenue: As of FY2025 Q3, the actual value is USD 123.32 K.

EPS: As of FY2025 Q3, the actual value is USD -0.06, beating the estimate of USD -0.12.

EBIT: As of FY2025 Q3, the actual value is USD -3.722 M.

Revenues for the three months ended September 30, 2025 were $123,319, compared to $0 for the same period in 2024. For the nine months ended September 30, 2025, revenues were $257,918, compared to $0 for the same period in 2024. The increase was due to revenue recognized under the agreement with Mayo Foundation for Medical Education and Research.

Net Loss: For the three months ended September 30, 2025, the net loss was - $3,050,373, compared to - $2,852,179 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was - $9,195,678, compared to - $8,234,897 for the same period in 2024.
Operating Loss: The operating loss for the three months ended September 30, 2025 was - $3,380,998, compared to - $3,309,128 for the same period in 2024. For the nine months ended September 30, 2025, the operating loss was - $10,190,600, compared to - $9,491,617 for the same period in 2024.
Research, Development and Patents Expenses: For the three months ended September 30, 2025, these expenses were $1,582,975, compared to $1,859,400 for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $5,611,429, compared to $5,287,318 for the same period in 2024.
General and Administrative Expenses: For the three months ended September 30, 2025, these expenses were $1,806,070, compared to $1,449,728 for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $4,605,468, compared to $4,204,299 for the same period in 2024.

Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $7,793,264, compared to - $8,711,232 for the same period in 2024.
Cash and Cash Equivalents: As of September 30, 2025, cash and cash equivalents were $32,562,612, compared to $40,359,738 as of December 31, 2024.

Core Business Focus: MediciNova, Inc. plans to advance its MN-166 (ibudilast) program through investigator-sponsored clinical trials, trials funded through government grants, and trials funded by the company. The company also intends to pursue strategic alliances to support further clinical development of MN-166 (ibudilast).
Non-Core Business: The company plans to advance the development of MN-001 (tipelukast) through investigator-sponsored trials with or without grant funding, as well as trials funded by the company.
Equity Financing: MediciNova, Inc. has entered into a Standby Equity Purchase Agreement with Yorkville, allowing the company to sell up to $30 million of its common stock over 36 months, subject to certain conditions.